Professor Grant McArthur is a Fellow of the Royal Australasian College of Physicians and holds a Ph.D. in Medical Biology. He is the Executive Director of the Victorian Comprehensive Cancer Centre; inaugural Lorenzo Galli Chair of Melanoma and Skin Cancers at the University of Melbourne and is a Senior Principal Research Fellow (NHMRC). He is also Head of the Molecular Oncology Laboratory and of the Cancer Therapeutics Program, Cancer Research, and a Senior Consultant Medical Oncologist, Cancer Medicine at the Peter MacCallum Cancer Centre.
Professor McArthur was the inaugural winner of the Translational Research Award of the Foundation Nelia et Amadeo Barletta, has held the Sir Edward Dunlop Clinical Cancer Research Fellowship of the Cancer Council of Victoria, won the inaugural Martin Lackmann medal for translational research, received the Medical Oncology Group of Australia’s Novartis Oncology Cancer Achievement Award and just recently, was the recipient of the prestigious Tom Reeve Award from Clinical Oncology Society of Australia (COSA) for 2018. He is a national and international study co-chair of a number of clinical trials of targeted therapies.
His research interests include discovery of novel drug targets in cancer, targeting oncogenes, immunological effect of targeted therapies, clinical trials of targeted therapeutics, personalised medicine, melanoma, cell cycle control, metabolism and protein synthesis in cancer.
Professor McArthur is on the editorial boards of Annals of Oncology, Anti-Cancer Drugs, the Journal of Clinical Oncology, the Open Clinical Cancer Journal, Therapeutic Advances in Medical Oncology and the Journal of Personalised Medicine.
He has published over 200 papers including senior or first author publications in the following journals: New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology, Cancer Discovery, Cancer Cell, Nature Cell Biology, Blood and EMBOJ.
The Tom Reeve Award for Outstanding Contributions to Cancer Care , Clinical Oncology Society of Australia (COSA)
Novartis Oncology Cancer Achievement Award, Medical Oncology Group of Australia (MOGA)
Nelia and Amadeo Barletta Foundation Translational Research Award